In this video, we take a closer look at the newest updates in Endocrinology. Watch for recent regulatory updates, promising pipeline results, and technology advances shaping the next wave of treatments.
Watch Our Video Summary Capturing Top Endocrinology News from the Last Two Weeks
Top Stories Covered in This Video
🧠 Parathyroidectomy linked to lower diabetes risk in PHPT [1] [07 Oct 2025]
Context: Retrospective Hong Kong health-system cohort, newly diagnosed classic PHPT; incident diabetes over median 2.8 years.
Key point: Surgery was associated with lower incident diabetes vs nonsurgical care (directional summary per source).
Implication: Could inform practice and payer discussions, interpretation depends on study design and confounding control.
🧬 Icovamenib shows sustained glucose control in T2D mid-stage study [2] [07 Oct 2025]
Context: Menin inhibitor, year-long mid-stage study; includes GLP-1 nonresponder subgroup; prior 2024 FDA hold resolved per company.
Key point: Company reports A1c reductions and persistence after discontinuation, with signals in insulin-deficient and GLP-1 nonresponder groups (endpoint details per source).
Implication: May influence prescriber choice and payer reviews pending full data.
📲 HealthTap joins LillyDirect for virtual diabetes care [3] [US • 08 Oct 2025]
Context: Reuters brief on telehealth integration with Lilly’s online platform.
Key point: HealthTap primary-care clinicians to offer medication management, labs, and preventive care via LillyDirect.
Implication: Could streamline initiation and adherence via remote prescribing and logistics.
🧪 GPX3 flagged as placental ferroptosis biomarker in GDM [4] [10 Oct 2025]
https://bioengineer.org/gpx3-crucial-biomarker-for-placental-ferroptosis-in-gdm/
Context: Bioinformatics plus clinical sample validation; gestational diabetes mellitus focus.
Key point: Study identifies GPX3 as a biomarker linked to placental ferroptosis in GDM (study design summary per source).
Implication: Could inform practice and payer discussions, interpretation depends on study design and confounding control.
🧪 PANTHERx to distribute MYCAPSSA for Chiesi [5] [US • 13 Oct 2025]
Context: MYCAPSSA is oral octreotide for acromegaly maintenance after octreotide or lanreotide response.
Key point: Chiesi named PANTHERx Rare as exclusive specialty pharmacy for MYCAPSSA distribution and support.
Implication: May expand screening, initiation, and follow-up at scale.
🌬️ FDA accepts Afrezza pediatric sBLA, PDUFA set [6] [US • 13 Oct 2025]
https://finance.yahoo.com/news/mannkind-announces-u-fda-accepts-120500519.html
Context: Submission supported by Phase 3 INHALE-1 in ages 4–17; Afrezza currently adult-approved.
Key point: FDA accepted MannKind’s sBLA for pediatric Afrezza with a 29 May 2026 target action date.
Implication: May influence prescriber choice and payer reviews pending full data.
📉 Orforglipron hits in two Phase 3 T2D studies [7] [15 Oct 2025]
Context: Late-phase program contrasts orforglipron vs dapagliflozin and vs placebo at Week 40.
Key point: Lilly reported primary endpoint success with A1c reductions and weight loss signals; fuller data pending.
Implication: May influence prescriber choice and payer reviews pending full data.
💉 Biocon Biologics and Civica launch private-label glargine in US [8] [US • 16 Oct 2025]
Context: Exclusive distributorship under Biocon’s existing approval; CalRx branding in California.
Key point: Biocon to supply, Civica to commercialize insulin glargine to broaden affordable US access.
Implication: Introduces competition that may affect pricing and formulary access.
Why it matters
- Surgical care in PHPT may carry metabolic benefits beyond calcium control.
- New T2D mechanisms, such as menin inhibition, seek durability beyond GLP-1 response.
- Platform care models integrate telehealth with pharma ecosystems to meet GLP-1 demand.
- Lower-cost insulin distribution models could reshape US access and pricing dynamics.
- Oral GLP-1 progress keeps pressure on incumbents across efficacy, convenience, and cost.
🚀 Accelerate your success. Contact us now
📂 Explore our case studies. See examples of our work.
💡 Read our insights. Learn from our latest reports and analysis
🎬 Watch on YouTube. Subscribe and never miss a video.
🧰 See our full range of services. Discover how we can help you.
FAQ
What did the PHPT study actually show about diabetes risk?
A retrospective cohort found parathyroidectomy was associated with lower incident diabetes compared with nonsurgical care in classic PHPT, across multiple sensitivity analyses
How durable were icovamenib’s effects in T2D?
The company reports sustained blood sugar reduction nine months after stopping therapy, with signals in GLP-1 nonresponders and insulin-deficient patients. Detailed endpoints remain per the mid-stage report
What services will HealthTap provide via LillyDirect?
Reuters reports virtual access to primary-care clinicians for medication management, lab review, and preventive care for US patients via Lilly’s platform
What changes with MYCAPSSA distribution?
Chiesi named PANTHERx Rare as the exclusive specialty pharmacy, aiming to improve access and patient support for oral octreotide in acromegaly
What is the status of Afrezza for pediatrics?
FDA accepted MannKind’s sBLA for ages 4–17, with a PDUFA target action date of 29 May 2026; submission draws on the INHALE-1 study
How strong are Lilly’s orforglipron data?
Topline shows primary endpoint success with A1c reductions vs placebo and dapagliflozin at Week 40; full secondary outcomes and safety data are pending a future meeting
Entities / Keywords
Primary hyperparathyroidism; parathyroidectomy; JAMA Surgery • Biomea Fusion; icovamenib; menin inhibitor; type 2 diabetes • LillyDirect; HealthTap; telehealth; GLP-1 demand • MYCAPSSA; octreotide; Chiesi; PANTHERx Rare; acromegaly • Afrezza; MannKind; pediatric sBLA; INHALE-1 • Orforglipron; Eli Lilly; oral GLP-1; Farxiga; dapagliflozin • Biocon Biologics; Civica; insulin glargine; CalRx.
References
- https://www.rheumatologyadvisor.com/news/parathyroidectomy-lowers-incident-diabetes-risk-in-primary-hyperparathyroidism/
- https://www.expresspharma.in/amp/biomea-fusion-reports-blood-sugar-control-with-icovamenib-in-type-2-diabetes-study/
- https://www.reuters.com/business/healthcare-pharmaceuticals/healthtap-joins-lillys-online-platform-offer-diabetes-management-services-2025-10-08/
- https://bioengineer.org/gpx3-crucial-biomarker-for-placental-ferroptosis-in-gdm/
- https://www.prnewswire.com/news-releases/pantherx-rare-selected-by-chiesi-for-the-distribution-of-mycapssa-302582168.html
- https://finance.yahoo.com/news/mannkind-announces-u-fda-accepts-120500519.html
- https://www.fiercebiotech.com/biotech/eli-lillys-orforglipron-bests-farxiga-padding-oral-glp-1-case-pair-phase-3-diabetes-wins
- https://www.biocon.com/biocon-biologics-and-civica-expand-partnership-and-launch-private-label-insulin-glargine-to-broaden-u-s-diabetes-treatment-options/